Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.74 USD
Change Today -0.07 / -0.59%
Volume 35.3K
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

nanostring technologies inc (NSTG) Snapshot

Open
$11.80
Previous Close
$11.81
Day High
$11.88
Day Low
$11.60
52 Week High
05/6/14 - $17.94
52 Week Low
10/13/14 - $7.80
Market Cap
215.6M
Average Volume 10 Days
93.7K
EPS TTM
$-2.90
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOSTRING TECHNOLOGIES INC (NSTG)

Related News

No related news articles were found.

nanostring technologies inc (NSTG) Related Businessweek News

No Related Businessweek News Found

nanostring technologies inc (NSTG) Details

NanoString Technologies, Inc. develops, manufacture, and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. The company provides nCounter Analysis System, an automated, multi-application, digital detection, and counting system that includes nCounter Prep Station, an automated liquid handling component for processing and preparing the samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nSolver Analysis software, a data analysis program that offers researchers the ability to quality check, normalize, and analyze their data. In addition, it provides Pan Cancer pathways gene expression panels, PanCancer immune profiling gene expression panels, gene expression panels, miRNA expression panels, and cancer copy number variation panels; custom CodeSets; and master kits that include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, as well as to clinical laboratories and medical centers for diagnostic use in North America, Europe, the Middle East, and the Asia Pacific. The company was founded in 2003 and is headquartered in Seattle, Washington.

276 Employees
Last Reported Date: 03/13/15
Founded in 2003

nanostring technologies inc (NSTG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $441.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $349.2K
Senior Vice President of Operations & Adminis...
Total Annual Compensation: $325.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.7K
Compensation as of Fiscal Year 2014.

nanostring technologies inc (NSTG) Key Developments

NanoString Technologies and University of Texas MD Anderson Cancer Center to Collaborate on Development of Multi-Omic Assays Simultaneously Profiling Gene and Protein Expression

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc. announced a multi-year collaboration to accelerate the development and adoption of a revolutionary new type of assay based on NanoString's nCounter Analysis System. The collaboration will involve the development of "multi-omic" assays, which simultaneously profile both gene and protein expression, with a primary focus on identifying important biomarkers in the burgeoning field of immuno-oncology as well as extending programs for targeting therapeutics. Key objectives of the collaboration include: development of new multi-omic assays and signatures that profile key oncology disease pathways and immune response from tumor tissue; incorporation of these multi-omic assays into select clinical studies being run at MD Anderson to predict response and monitor response to cancer immuno-therapies and targeted therapies, both as single agents and combinations; and identification of clinically actionable proteomic markers across multiple tumor types. Under the terms of the agreement, NanoString is granted rights to research and diagnostic content developed within the scope of the collaboration.

NanoString Technologies, Inc. Appoints Robert Hershberg to its Board of Directors

NanoString Technologies, Inc. has appointed Robert Hershberg to its board of directors. Dr. Hershberg brings to the Board extensive executive and board level expertise in the fields of immuno-oncology and translational medicine, as well as a passion for the advancement of early cancer screening technologies. He joined Celgene Corporation in July 2014 as Senior Vice-President of Immuno-Oncology. Dr. Hershberg is also the founder, President and CEO of VentiRx Pharmaceuticals, Inc. and serves as an independent member of the Board of Directors of Adaptive Biotechnologies Corp. Previously, he was Chief Medical Officer of Dendreon Corporation, and vice president, Medical Genetics of Corixa Corporation.

NanoString Technologies Appoints Robert Hershberg to Board of Directors

NanoString Technologies, Inc. announced that Robert Hershberg has been appointed to its Board of Directors, effective March 2, 2015. The Board now consists of six members. He joined Celgene Corporation, a publicly-traded biopharmaceutical company, in July 2014 as Senior Vice-President of Immuno-Oncology and currently leads Celgene's research and early development efforts across its immuno-oncology portfolio. He also oversees the newly formed Celgene Immuno-Oncology Center of Excellence in Seattle, Washington, which is focused on Translational Medicine ranging from basic immunology/biomarker development, immuno-profiling, systems immunology and early clinical development of existing and novel compounds.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSTG:US $11.74 USD -0.07

NSTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.85 USD +0.15
Exiqon A/S kr10.60 DKK +0.10
Pacific Biosciences of California Inc $6.21 USD +0.055
Response Genetics Inc $0.31 USD -0.029
WaferGen Bio-systems Inc $4.63 USD -0.11
View Industry Companies
 

Industry Analysis

NSTG

Industry Average

Valuation NSTG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSTRING TECHNOLOGIES INC, please visit www.nanostring.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.